As one of the major exporters of APIs in the world, India, which is in the second wave of the epidemic, is affecting the API market.
According to the latest data released by the Ministry of Health of India on April 25, India has newly confirmed 349691 cases and 2767 new deaths in a single day, with a total of 192,311 deaths. Data shows that India has more than 300,000 new confirmed cases in a single day, surpassing the previous world record of 297,000 new cases in a single day created by the United States. The Indian government predicted on the 25th that the country’s new crown epidemic may reach its peak in mid-May when the number of newly diagnosed cases will be as high as 500,000 every day.
Zhang Wenhong, director of the Department of Infectious Diseases at Shanghai Huashan Hospital, also publicly stated on social platforms that even if India is speeding up vaccination now, it is too late, and a larger outbreak is still to come.
Affected by the news, the domestic API stocks soared again this morning, among which Minova has the daily limit for 3 consecutive trading days.
Manova takes the lead in the bulk drug sector
According to the data, Manova is a pharmaceutical manufacturing company specializing in the research and development, production, and sales of specialty APIs (including intermediates) and finished drugs. Its main business includes specialty API business, API CDMO business, and preparation business. High brand awareness and competitive advantage have been formed in the sub-industry of specialty APIs, and a leading market position has been gradually established. According to the announcement, the company is also one of Ningbo’s top 100 manufacturing competitiveness enterprises, China’s top 100 international pharmaceutical companies, high-quality suppliers and partners in the international market (ranked 60), and its core products cover cardiovascular, central nervous system, gastrointestinal digestion Dao and other therapeutic fields, it is one of the companies that export the largest variety of European specialty APIs in China. It is closely related to internationally renowned companies such as KRKA, Servier, Bayer, GEDEON RICHTER, and SANOVEL. Pharmaceutical companies have established long-term, deep, and stable cooperative relations. The announcement also shows that Manova has recently signed a “Strategic Business Cooperation Agreement” with Merck’s subsidiary Interview International Co., Ltd. (INTERVETINTERNATIONALB.V., an animal health company under Merck, also known as MSDAnimalHealth, hereinafter referred to as “Merck”). It may be one of the reasons that caused the stock price to soar Spark Global Limited.
In addition to Manova, a number of other API-related concept stocks are also rising sharply.
Such as the new stock common pharmaceutical industry intraday daily limit. According to company data, Common Pharmaceutical is a high-tech enterprise specializing in the R&D, production, and sales of steroidal drug raw materials. The main products are the starting materials and intermediates required for the production of steroidal drugs. In the field of steroid drug starting materials, it is one of the largest domestic suppliers; in the field of steroid drug intermediates, the company has mastered the production technology of a variety of products, and realized a complete product route from starting materials to sex hormone intermediates Covers and can produce a variety of corticosteroid intermediates and progesterone intermediates. The product line is rich, which can meet the diversified needs of customers and is recognized by the market.